THINKWELL PSYCHOLOGY, ATTADALE, WA
  • Home
  • Services
  • Approaches
    • Cognitive Behaviour Therapy (CBT)
    • Interpersonal Psychotherapy (IPT)
    • Mindfulness
    • Mindfulness-Based Cognitive Therapy
    • Acceptance and Commitment Therapy (ACT)
    • Dialectical Behaviour Therapy (DBT)
    • Neuropsychotherapy
    • Schema Focused Therapy
    • Eye movement desensitization and reprocessing (EMDR)
    • Emotion Focused Therapy (EFT)
  • Our Team
    • PRACTICE GALLERY
  • NEWS
  • Booking
  • Contact
​15B / 550 Canning Hwy, ​Attadale
☎ 6361 1275
REQUEST APPOINTMENT ►
IMPORTANT MESSAGE REGARDING THE COVID -19 (Corona Virus)

Due to the Corona Virus we respectfully request that all clients and and prospective clients who have recently travelled overseas, have flu like symptoms or have been in contact with someone who has contracted Virus to please reschedule or make an appointment after the 2 week quarantine period in accordance with the WA Health Department guidelines.

We appreciate your co-operation in the interest of the community and staff at Thinkwell Psychology.

New Therapeutic Target for Depression Identified

5/24/2019

 
Re-published from "Neuroscience News" magazine from TechnologyNetworks.
Original story by the University of Malaga
New Therapeutic Target for Depression Identified
Photo by Paweł Czerwiński on Unsplash
Depression is one of the most widespread disorders that affects society, according to the World Health Organization. In fact, it is estimated that 4 million people are affected in Spain.

There are different pharmacological treatments for depression, mainly therapies that act on the serotonin system -the so-called SSRIs (selective serotonin reuptake inhibitors). However, it has been evidenced that these antidepressants take around two weeks to have an effect and, what's more, around 30% of patients are resistant to this drug.

Researchers of the Department of Human Physiology of the UMA Faculty of Medicine have taken a step closer to a new therapeutic target to face this mental disorder.
Particularly, the group of "Neurochemistry of the Transmission in the Central Nervous System", co-directed by Professor Zaida Díaz-Cabiale, has evidenced that a fragment of the "Galanin" neuropeptide -an endogenous molecule of the brain- is involved in anhedonia, which is the loss of the capacity to feel pleasure in daily activities, for instance, meals, social activity or sex, and, thus, one of the main symptoms in depressed patients.

These researchers have demonstrated for the first time the role of "GAL (1-15)" in the brain reward system of an animal model.

"We have verified through different experiments how animals modify their response to high-reinforcement appetitive stimuli, such as saccharine or sexual attraction, after the administration of the Galanin fragment", explains researcher Carmelo Millón, one of the authors of this study, published in Journal of Psychopharmacology.

Furthermore, in this article, in which a researcher of Karolinska Institute (Sweden) has participated, they have analyzed the brain reinforcement system at a molecular level, the circuit in charge of reinforcing positive behavior for individuals and species, and reaffirmed that the Galanin fragment acts directly on this neurological mechanism, reducing the circuit activity.

According to Millón, describing this fragment is essential to modulate the brain reward circuit, having interesting applications that go beyond treatments for depression, such as its possible use in drug-related addictions. "The understanding of these mechanisms opens the way for endless therapeutic strategies, hence its importance", he says.

The research group of "Neurochemistry of the Transmission in the Central Nervous System" has been studying the Galanin molecule for more than two decades, originally in cardiovascular regulation. Its role in neuropsychiatric diseases, such as depression or anxiety, started to be investigated in the UMA in 2007.

This article has been republished from materials provided by the University of Malaga. Note: material may have been edited for length and content. For further information, please contact the cited source.

Reference: 
Carmelo Millón et al. Role of the galanin N-terminal fragment (1-15) in anhedonia: Involvement of the dopaminergic mesolimbic system, Journal of Psychopharmacology (2019). DOI: 10.1177/0269881119844188

Source: Neuroscience News, Technology Networks

Comments are closed.

    Categories

    All
    Achieving A Balanced Life
    Achieving Purpose And Direction
    Adolescence
    Anxiety
    Behaviour
    Body Image
    Brain Research
    Cognitive Behavioural Therapy
    Couples Counselling
    Depression Management
    Disorders
    Grief
    Handling Trauma
    Health Research
    Healthy Digital Life
    Improving Self Worth
    Improving Self-worth
    Life Style
    Loneliness
    Manage Challenges
    Medicare
    Mental Health
    Neuropsychotherapy
    Neuroscience
    OCD
    Parenting
    Personal Development'
    Personal Relationships
    Reducing Stress
    Wellbeing

    RSS Feed

Thinkwell Psychology Perth


15B / 550 CANNING HIGHWAY
ATTADALE  (ATTADALE BUSINESS CENTRE)

PH: (08) 6361 1275   |   FAX: (08) 6361 1318 
Health rebates available at Thinkwell Psychology
Bookings

Dr Teresa D'Amato
TERESA D’AMATO
CLINICAL PSYCHOLOGIST
B.A. Psych (Hons) | M. Psych (Clinical) | MAPS | MACPA | MIAAN
EMAIL
Professional Membership Thinkwell Psychology

Copyright  ©2023 Thinkwell Psychology. All rights reserved.
Website developed by Ablaze Marketing
  • Home
  • Services
  • Approaches
    • Cognitive Behaviour Therapy (CBT)
    • Interpersonal Psychotherapy (IPT)
    • Mindfulness
    • Mindfulness-Based Cognitive Therapy
    • Acceptance and Commitment Therapy (ACT)
    • Dialectical Behaviour Therapy (DBT)
    • Neuropsychotherapy
    • Schema Focused Therapy
    • Eye movement desensitization and reprocessing (EMDR)
    • Emotion Focused Therapy (EFT)
  • Our Team
    • PRACTICE GALLERY
  • NEWS
  • Booking
  • Contact